Vodafone and AstraZeneca announced today a global partnership to use mobile health (mHealth) services to improve health outcomes for patients with cardiovascular conditions. The collaboration will create new mobile and internet-based services to support patients through their treatment journey, improving medication adherence and giving patients confidence to manage their condition more effectively.
Vodafone will provide the technology, infrastructure and expertise for these services, as well as the ability to capture data from a variety of sources to improve overall engagement between patients and their Health Care Professionals (HCPs).
HCPs will be able to give patients the option to use these mHealth services, as an integral part of the patient care process, empowering them to manage their conditions as part of their daily routine. Patients will have access to educational material – personalised for their needs – and will benefit from coaching and treatment support to help manage their medication and lifestyle changes, and track their treatment progress.
The project will be led by the Intelligent Pharmaceutical Group within AstraZeneca, part of Global Medicines Development, working in close collaboration with the in-country marketing teams. Services will be designed to work across geographies, with the ability to adapt to local variations in regulations and patient care. Astra Zeneca has selected Vodafone in light of Vodafone’s experience in delivering – and ability to scale – mHealth services.
Vodafone Director for Machine to Machine, Erik Brenneis, said, “Bringing together the best in connectivity with the best in treatment and education will create powerful and compelling outcomes for patients. AstraZeneca is a global leader in the mHealth field and we are delighted to work with them to develop these innovative services.”
Andy Jones VP Pharmaceutical Innovation at AstraZeneca commented, “It is really exciting to see the progress being made in this area. This work is an excellent example of collaboration between AstraZeneca and Vodafone. Together we believe we are delivering something that will bring real benefit to patients in this important therapeutic area.”
For further information:
Vodafone UK Media Relations
+44 1635 666777
Vodafone is one of the world’s largest telecommunications companies with approximately 419 million customers in its controlled and jointly controlled markets as of 31 December 2013. Vodafone has equity interests in telecommunications operations in nearly 30 countries and around 50 partner networks worldwide. For more information, please visit: www.vodafone.com
About Vodafone Machine-to-Machine (M2M) communications
Vodafone Machine-to-Machine (M2M) connects previously isolated machines or devices to the internet, delivering new functionality and enhanced services without the need for human intervention. Supported by more than 250 dedicated employees, Vodafone’s global M2M platform makes it easy for global businesses to manage centrally M2M deployments across multiple territories, with greater control and at a lower cost than previously possible. For more information, please visit: https://m2m.vodafone.com/home/
Follow us on Twitter: @vodafone_m2m
Or our website: http://m2m.vodafone.com/insight_news
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com